Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

While Amgen Sees Success For Two Growth Drivers, Headwinds Remain

Breakthrough Drugs Sotorasib, Tezepelumab Edge Closer To Market

Executive Summary

Scrip discussed key wins for sotorasib in lung cancer and tezepelumab in asthma with Amgen executives Murdo Gordon and David Reese, but COVID-19 and other challenges are looming.

You may also be interested in...



Amgen Is Still ‘A Biotech At Heart’

Head of Amgen’s inflammation business, Kave Niksefat, gives insight into how the 40-year-old biotech maintains its culture of innovation and avoids falling into the “trap” of bureaucracy.

Amgen’s Sotorasib Updates Raise New Questions For KRAS Program

The company provided updates on the timing of some data from its extensive clinical program for its KRAS G12C inhibitor Lumakras, but not for certain high-profile combinations.

Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody

Five Prime’s Phase III-ready bemarituzumab could offer significant revenue for Amgen, particularly in Asia, but analysts ask if the buyout is a precursor to greater deal making by Amgen.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel